Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Nhs England
Headquarters: Leeds, United Kingdom
Website: https://www.england.nhs.uk
Year Founded: N/A
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Nov 21, 2023
Politics, Policy & Law
U.K., ABPI agree to new voluntary pricing scheme
Five-year deal allows increased spending growth, incentivizes uptake of new medicines
BioCentury | Nov 16, 2023
Regulation
Scientific achievement, access questions define the world’s first gene editing approval
Casgevy from Vertex and CRISPR gains the first gene editing approval, via U.K. decision
BioCentury | Sep 1, 2023
Finance
The Cystic Fibrosis Powerhouse: Vertex
Back to School 2023 case study: How Vertex kept raising the bar to dominate a therapeutic space
BioCentury | Jul 20, 2023
Market Access
U.K. proposes model to value any antimicrobial as a subscription
Getting other countries to adopt similar strategies will be key to stimulating antibiotics development, says John Rex
BioCentury | Jul 6, 2023
Politics, Policy & Law
U.K. unveils cancer vaccine program, deal with BioNTech to improve patient access
Initiative part of push to improve clinical trial participation
BioCentury | Mar 2, 2023
Politics, Policy & Law
U.K. industry group proposes fixed rebate for new pricing deal
Deal would include industry fund to invest in NHS resources, but remove cap on medicines spend
BioCentury | Jan 7, 2023
Deals
Jan. 6 Quick Takes: Pfizer ‘externalizing’ some cancer, rare disease programs
Plus: Column Group leads Synthekine’s $100M series C, and updates from Amolyt, Perceive, bluebird bio, BioNTech and more
BioCentury | Jun 17, 2022
Market Access
U.K. paying for two antibiotics in world first subscription model
NICE’s QALY-based calculation for Zavicefta, Fetcroja goes far beyond simply modeling their health benefits
BioCentury | Sep 11, 2021
Deals
NHS-Novartis deal could change how pharmas work with integrated systems
Novartis has already started to engage healthcare systems around the world
BioCentury | Aug 13, 2021
Product Development
Indications, not platforms, drive growth at Vertex
Vertex is applying the same serial innovation strategy it used for CF to other indications
Items per page:
1 - 10 of 179